首页> 外文期刊>Journal of diabetes and its complications >Diabetes and macrovascular disease.
【24h】

Diabetes and macrovascular disease.

机译:糖尿病和大血管疾病。

获取原文
获取原文并翻译 | 示例
           

摘要

Cardiovascular disease (CVD) is the major cause of morbidity and mortality in patients with diabetes. Macrovascular events, including stroke, myocardial infarction (MI), and peripheral arterial disease (PAD), occur earlier than in nondiabetics and the underlying pathologies are often more diffuse and severe. Diabetic arteriopathy, which encompasses endothelial dysfunction, hypercoagulability, changes in blood flow, and platelet abnormalities, contributes to the early evolution of these events. Tight glucose and blood pressure control improves the vascular status of these patients by varying degrees. Antiplatelet agents have also been shown to be effective in the secondary prevention of cardiovascular events. In the ideal world, every risk factor would be addressed and each diabetic would have excellent glycemic control, a low normal blood pressure, a low LDL, and be prescribed an ACE inhibitor, together with aspirin and clopidogrel. If this is done, this emerging epidemic of macrovascular disease will be contained.
机译:心血管疾病(CVD)是糖尿病患者发病和死亡的主要原因。包括中风,心肌梗塞(MI)和外周动脉疾病(PAD)在内的大血管事件发生的时间比非糖尿病患者要早,并且其潜在的病变通常更为弥散和严重。糖尿病性动脉病包括内皮功能障碍,高凝性,血流变化和血小板异常,有助于这些事件的早期发展。严格的葡萄糖和血压控制可以不同程度地改善这些患者的血管状况。抗血小板药也已显示出对心血管事件的二级预防有效。在理想的世界中,将解决所有危险因素,并且每个糖尿病患者都应具有出色的血糖控制,正常血压低,LDL低,并与阿司匹林和氯吡格雷一起服用ACE抑制剂。如果这样做,将遏制这种正在出现的大血管疾病流行病。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号